Journal
CANCER INVESTIGATION
Volume 28, Issue 9, Pages 885-895Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2010.512816
Keywords
Pancreatic cancer; APE1/Ref-1; siRNA; cell cycle
Categories
Funding
- NCI NIH HHS [R21 CA122298, R01 CA114571, R01 CA121168-02S1, R01 CA114571-04, R01 CA094025, R01 CA106298-05, R21 CA122298-02, R01 CA094025-05, R01 CA121168, R01 CA106298] Funding Source: Medline
Ask authors/readers for more resources
Pancreatic cancer is a deadly disease that is virtually never cured. Understanding the chemoresistance intrinsic to this cancer will aid in developing new regimens. High expression of APE1/Ref-1, a DNA repair and redox signaling protein, is associated with resistance, poor outcome, and angiogenesis; little is known in pancreatic cancer. Immunostaining of adenocarcinoma shows greater APE1/Ref-1 expression than in normal pancreas tissue. A decrease in APE1/Ref-1 protein levels results in pancreatic cancer cell growth inhibition, increased apoptosis, and altered cell cycle progression. Endogenous cell cycle inhibitors increase when APE1/ Ref-1 is reduced, demonstrating its importance to proliferation and growth of pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available